136 related articles for article (PubMed ID: 34140260)
41. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
42. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
43. R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.
Bašić-Kinda S; Radman I; Dujmović D; Ilić I; Kralik M; Dobrenić M; Galunić-Bilić L; Rončević P; Vodanović M; Sertić Z; Hude I; Aurer I
Ann Hematol; 2021 Jun; 100(6):1517-1524. PubMed ID: 33216199
[TBL] [Abstract][Full Text] [Related]
44. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
46. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.
Shin DY; Byun BH; Kim KM; Kang JH; Lim I; Kim BI; Lee SS; Choi CW; Kang HJ; Lim SM
Cancer Chemother Pharmacol; 2016 Oct; 78(4):825-31. PubMed ID: 27577259
[TBL] [Abstract][Full Text] [Related]
47. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
[TBL] [Abstract][Full Text] [Related]
48. Treatment strategies for aggressive lymphomas: what works?
Wilson WH
Hematology Am Soc Hematol Educ Program; 2013; 2013():584-90. PubMed ID: 24319235
[TBL] [Abstract][Full Text] [Related]
49. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
51. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Casasnovas RO; Meignan M; Berriolo-Riedinger A; Bardet S; Julian A; Thieblemont C; Vera P; Bologna S; Brière J; Jais JP; Haioun C; Coiffier B; Morschhauser F;
Blood; 2011 Jul; 118(1):37-43. PubMed ID: 21518924
[TBL] [Abstract][Full Text] [Related]
52. Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y; Tsukamoto T; Kawata E; Uoshima N; Uchiyama H; Yokota I; Maegawa S; Takimoto T; Tanba K; Matsumura-Kimoto Y; Kuwahara-Ota S; Fujibayashi Y; Yamamoto-Sugitani M; Chinen Y; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Cancer Med; 2018 Mar; 7(3):655-664. PubMed ID: 29473332
[TBL] [Abstract][Full Text] [Related]
53. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
54. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
55. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
Gisselbrecht C; Lepage E; Molina T; Quesnel B; Fillet G; Lederlin P; Coiffier B; Tilly H; Gabarre J; Guilmin F; Hermine O; Reyes F;
J Clin Oncol; 2002 May; 20(10):2472-9. PubMed ID: 12011124
[TBL] [Abstract][Full Text] [Related]
56. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
57. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
58. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
59. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
[TBL] [Abstract][Full Text] [Related]
60. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]